The Leukaemia Research Group is headed by Professor MD Håkon Reikvam.
The research has a major focus on the hematological malignancy acute myeloid leukaemia (AML); an aggressive disease that can be cured only by intensive chemotherapy eventually in combination with stem cell transplantation. Our main research areas are:
- Biological and functional characterization of primary human AML cells and their interactions with stromal elements
- Experimental studies of efficiency and toxicity (especially immunotoxicity) of both new targeted therapies and already established therapeutic strategies in human AML.
Collaborators
Key collaborators at the University of Bergen:
Researcher Kjell Petersen, CBU Service Group
Professor Frode Berven, Institute of Biomedicine
Professor Bjørn Tore Gjertsen, Institute of Clinical Science
Professor Lars Herfindal, Institute of Clinical Science
Professor Karl Johan Trondstad, Institute of Biomedicine
Key collaborators at Haukeland University Hospital:
Associate Professor Randi Hovland, Department of Medical Genetics, Haukeland University Hospital
External collaborators:
Dr.Tor Henrik Tvedt, The national Hospital, University of Oslo
Professor Jean-Emmanuel Sarry, Universite Toulouse III-Paul Sabatier, France
Professor Jerome Tamburini, University of Geneva, Switzerland.
Professor Kristian Koenecke, University of Hannover, Germany.
Funding:
University of Bergen
Norwegian Cancer Society
Helse Vest
Haukeland University Hospital
Norsk indremedisinsk forening
Caroline Musæus Aarsvolds fond
Rakel og Otto Kr. Bruuns legat
Øyvinn Mølbach-Petersen fond
